Literature DB >> 29376552

Impact of a fracture liaison service on patient management after an osteoporotic fracture: the CHUV FLS.

Bérengère Aubry-Rozier1, Delphine Stoll1, Elena Gonzalez Rodriguez1, Didier Hans1, Veronique Prudent1, Ariane Seuret1, Alain Farron2, Olivier Lamy1.   

Abstract

In 2008, the Centre Hospitalier Universitaire Vaudois (CHUV, Lausanne, Switzerland) initiated a Fracture Liaison Service (FLS). All patients hospitalised for a low trauma fracture are identified by the FLS. Inpatients then choose to be managed by either the FLS team or their general practitioner (GP). In this study we compared the management between the FLS team and the GP in terms of diagnosis of osteoporosis, treatment, refracture rates and mortality after FLS recording. Results are compared with the management of osteoporosis before the creation of the FLS, as reported in the survey study Osteocare. A total of 606 patients were included (80% women); 55% chose management by the FLS and 45% their GP. The mean age was 78.5, and hip was the main fracture site (44%). The percentage of patients having dual X-ray absorptiometry to diagnose osteoporosis was significantly higher in the FLS group than the GP group (72 vs 26.5%, p <0.01). This percentage was 31.4% in the Osteocare study. Overall, 50.3% of patients in the FLS group had osteoporosis versus 57.5% in the GP group (p <0.05). This percentage was 46.0% in the Osteocare study. Use of osteoporosis medication was higher in the FLS group (FLS 100% of the patients, GP 44.1%, p <0.001) and had increased since the Osteocare study (21.6%). One-year nonvertebral refracture rate was higher in GP group than in the FLS patients (5.1 vs 3.0%, p <0.05), whereas more vertebral fractures were identified in the FLS group, owing to protocol-driven regular clinical and vertebral fracture assessment (VFA) evaluations (number of evaluations 8 vs 0, p <0.01). Unadjusted mortality was higher in GP group than in the FLS group at one and five years (6.93 vs 2.11% and 33.58 vs. 15.96%, p <0.04). After adjustment by age and fracture site, these results were not significant. With FLS management, diagnosis and treatment of osteoporosis were more frequent than with GP management; new nonvertebral fractures were less frequent. Moreover, both forms of management had increased relative to rates reported in a 2004-2006 nationwide survey Osteocare, before FLS creation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29376552     DOI: 10.4414/smw.2018.14579

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  5 in total

1.  Multiple simultaneous fractures are associated with higher all-cause mortality: results from a province-wide fracture liaison service.

Authors:  R Sujic; J Luo; D E Beaton; E R Bogoch; J E M Sale; S Jaglal; R Jain; M Mamdani
Journal:  Osteoporos Int       Date:  2019-11-13       Impact factor: 4.507

2.  Hybrid stabilization of unstable osteoporotic thoracolumbar vertebral body fractures: clinical and radiological outcome after a mean of 4 years.

Authors:  Ulrich J Spiegl; Christine Anemüller; Jan-Sven Jarvers; Nicolaus von der Höh; Christoph Josten; Christoph-Eckhard Heyde
Journal:  Eur Spine J       Date:  2019-03-21       Impact factor: 3.134

3.  Midterm outcome after posterior stabilization of unstable Midthoracic spine fractures in the elderly.

Authors:  U J Spiegl; P-L Hölbing; J-S Jarvers; N V D Höh; P Pieroh; G Osterhoff; C-E Heyde
Journal:  BMC Musculoskelet Disord       Date:  2021-02-15       Impact factor: 2.362

4.  The effectiveness of Police General Hospital's fracture liaison service (PGH's FLS) implementation after 5 years: A prospective cohort study.

Authors:  Tanawat Amphansap; Nitirat Stitkitti; Alisara Arirachakaran
Journal:  Osteoporos Sarcopenia       Date:  2020-11-25

5.  Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip fracture in Japan.

Authors:  Shinichi Nakatoh; Kenji Fujimori; Junko Tamaki; Nobukazu Okimoto; Sumito Ogawa; Masayuki Iki
Journal:  J Bone Miner Metab       Date:  2020-03-07       Impact factor: 2.626

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.